Last updated 32 days ago
A Study of Atezolizumab Versus Placebo as Adjuvant Therapy in Patients With High-Risk Muscle-Invasive Bladder Cancer Who Are ctDNA Positive Following Cystectomy
800 patients around the world
Available in Argentina, United States, Brazil, Spain
Hoffmann-La Roche
19Research sites
800Patients around the world
This study is for people with
Bladder Cancer
Muscle-Invasive Bladder Cancer
Requirements for the patient
From 18 Years
All Gender
Medical requirements
Sites
CEMIC - Hospital Universitario Sede Saavedra - CABA, Buenos Aires
Recruiting
Instituto Médico Especializado Alexander Fleming - CABA, Buenos Aires
Recruiting
Centro Médico Austral OMI - CABA
Recruiting
Hospital Erasto Gaertner
Recruiting
CETUS Hospital Dia Oncologia - Belo Horizonte
Recruiting
Clínica Viver - Santa Maria
Recruiting
Instituto do Câncer do Estado de São Paulo "Octavio Frias de Oliveira" - ICESP
Recruiting
Beneficência Portuguesa de São Paulo
Recruiting
Hospital Moinhos de Vento
Recruiting
Hospital São Lucas da Pontifícia Universidade Católica do Rio Grande do Sul
Recruiting
StudyIMvigor011
SponsorHoffmann-La Roche
Study typeInterventional
Conditions
Muscle-Invasive Bladder Cancer
Requirements
From 18 YearsAll Gender
Unique study IDclinicaltrials.gov
NCT04660344
